

Part 3. Capsid Assembly Modulator (CAM-E) Mechanism of Action References

1. Vendeville S, Amblard F, Bassit L, et al. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075. *J Med Chem*. 2024;67(23):21126-21142.
2. Yuen MF, Agarwal K, Jucov A, et al. ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial. *Lancet Gastroenterol Hepatol*. 2026;11(3):218-231.
3. Berke JM, Dehertogh P, Vergauwen K, et al. Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. *Antimicrob Agents Chemother*. 2017;61(8):e00560-17.
4. Taverniti V, Ligat G, Debing Y, Kum DB, Baumert TF, Verrier ER. Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives. *J Clin Med*. 2022;11(5):1349.
5. Debing Y, Verheyen J, Vanrusselt H, et al. ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development [poster #570]. EASL Congress 2026; May 28, 2026; Barcelona, Spain. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-easl-congress-2026>
6. Verheyen J, et al. Capsid assembly modulator ALG-001075 prevents cccDNA formation and HBV DNA integration in vitro [poster #1251]. The Liver Meeting® (AASLD); November 7, 2025; Washington, DC. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-liver-meetingr-2025/>
7. Burdette DL, Lazerwith S, Yang J, et al. Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy. *PLoS One*. 2022;17(4):e0262516.
8. Gane E, Schwabe C, Wu M, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants. *Antivir Ther*. 2025;30(6):13596535251392955. doi:10.1177/13596535251392955.
9. Yuen MF, et al. Monotherapy with the capsid assembly modulator, ALG-000184, results in high viral suppression rates in untreated HBeAg+ and HBeAg- subjects with chronic hepatitis B [poster #1213]. The Liver Meeting® (AASLD); November 15-19, 2024; San Diego, CA. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-liver-meeting-tlm>
10. Yuen MF, et al. Monotherapy with the novel capsid assembly modulator ALG-000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection [poster #THU-261]. EASL Congress 2025; May 8, 2025; Amsterdam, Netherlands. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-easl-congress-2025>

11. Hou J, et al. The safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with entecavir for up to 96 weeks in untreated HBeAg-positive subjects with chronic hepatitis B virus infection [poster #856]. EASL Congress 2025; May 8, 2025; Amsterdam, Netherlands. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-easl-congress-2025>
12. Yuen MF, et al. Oral once-daily 300 mg ALG-000184, a novel capsid assembly modulator, demonstrates potent suppression of HBV DNA in treatment-naïve or currently-not-treated subjects with chronic HBV [oral presentation #0198]. The Liver Meeting® (AASLD); November 9, 2025; Washington, DC. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-liver-meetingr-2025/>
13. Mak LYL, Jekle A, Anderson M, et al. Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy [poster #588]. EASL Congress 2026; May 27, 2026; Barcelona, Spain. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-easl-congress-2026>
14. Aligos Therapeutics. FDA grants fast track designation to pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection. Press release; April 14, 2026. <https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-announces-first-interim-analysis-results-phase>
15. Aligos Therapeutics. Pipeline overview. <https://www.aligos.com/pipeline/>